Comparative Studies of Biosimilar Medicinal Products

QR Code

Comparative Studies of Biosimilar Medicinal Products

The article describes specific aspects of biosimilars research and development. The aim of the study was to analyse the ways to conduct comparative studies of biotechnological medicinal products and the main approaches to the assessment of the obtained data. The paper highlights that biotechnologica...

Full description

Saved in:

Bibliographic Details
Main Author:	O. B. Talibov
Format:	Article
Language:	Russian
Published:	Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’) 2019-06-01
Series:	Регуляторные исследования и экспертиза лекарственных средств
Subjects:	biotechnological medicinal products monoclonal antibodies biosimilars microheterogeneity post-translational modification pharmacokinetics pharmacodynamics clinical trials
Online Access:	https://www.vedomostincesmp.ru/jour/article/view/229
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Studying the pharmacokinetics of biotechnological medicinal products on the example of monoclonal antibodies
by: V. V. Smirnov, et al.
Published: (2023-06-01)

Results of the Estimation of Biosimilarity of RinLiz<sup>®</sup> (LLC «GEROPHARM», Russia) and Humalog<sup>®</sup> (Lilly France, France) Using the Method of the Hyperinsulinemic Eulygemic Clamp on Healthy Voluntary
by: A. Yu. Mayorov, et al.
Published: (2020-05-01)

Review of the textbook “Clinical and pharmacological characteristics of biotechnological drugs: from classifications to adverse events”
by: V. I. Petrov
Published: (2024-04-01)

First available biosimilar monoclonal antibodies
by: Zh. I. Avdeeva, et al.
Published: (2018-02-01)

Reorganization of public procurement of biosimilars and its economic effect on the monoclonal antibody market in Russia
by: A. Yu. Efremov, et al.
Published: (2025-05-01)

Physico-Chemical and Biological Properties of Biosimilar and Reference Tissue Plasminogen Activator Products
by: V. D. Gusarova, et al.
Published: (2019-03-01)

Biological and Biosimilar Medicines in Contemporary Pharmacotherapy for Metabolic Syndrome
by: Wiktoria Górecka, et al.
Published: (2025-06-01)

Authorisation of Non-Innovator Biotherapeutic (Biosimilar) Products in the USA
by: A. A. Soldatov, et al.
Published: (2019-03-01)

Identification of tyrosine sulfation in the variable region of a bispecific antibody and its effect on stability and biological activity
by: Christopher B. Lietz, et al.
Published: (2023-12-01)

Pharmacotherapy variability and precision medicine in neurocritical care
by: Sherif Hanafy Mahmoud, et al.
Published: (2025-07-01)

International standards for monoclonal antibodies for assessing the biological activity of medicines: A status update
by: L. A. Gayderova, et al.
Published: (2023-12-01)

Biosimilars - drugs of the future
by: E. A. Eltcova, et al.
Published: (2014-04-01)

A phase I, randomized, double-blind, parallel, single-dose pharmacokinetic study to evaluate the biosimilarity of KM118 (proposed pertuzumab biosimilar) with reference pertuzumab (Perjeta®) in healthy male subjects
by: Yan Li, et al.
Published: (2025-12-01)

Considerations for the Bioanalytical Part of Equivalence Studies of Biosimilar Nadroparin Calcium
by: V. M. Kosman, et al.
Published: (2023-03-01)

A Double-blind Randomized Comparative Phase I Study to Assess Biosimilarity and Immunogenicity of "Trastuzumab" (LLC "Mabscale", Russia) and Herceptin® (F. Hoffmann-La Roche Ltd., Switzerland) in Healthy Volunteers
by: M. A. Kolganova, et al.
Published: (2023-09-01)

Comparing the original and biosimilar biotherapeutics of the monoclonal antibody eculizumab by intact mass measurement and middle-up mass spectrometry analysis
by: M. B. Degterev, et al.
Published: (2021-03-01)

Demonstration of Quality, Safety and Efficacy of Biological Products Subject to Changes in Their Manufacturing Process
by: A. N. Asiliev, et al.
Published: (2020-05-01)

Biosimilar of biphasic human insulin: results of a double-blind, randomized, comparative, cross-sectional clinical study of pharmacokinetics
by: Tatyana Karonova, et al.
Published: (2019-09-01)

The safety of biological preparations. Part 2. Safety issues of biosimilars
by: A. A. Soldatov, et al.
Published: (2018-02-01)

Integrating Personal Health Records to Improve Data Integrity in Trials With Decentralized Elements: A Pilot Study
by: Yoonjin Kim, et al.
Published: (2025-06-01)

Pharmacological incompatibility
by: A. I. Vengerovsky
Published: (2003-09-01)

Prediction of Monoclonal Antibody Pharmacokinetics in Pediatric Populations Using PBPK Modeling and Simulation
by: Chiara Zunino, et al.
Published: (2025-07-01)

Utility of physiologically based pharmacokinetic modeling to predict inter-antibody variability in monoclonal antibody pharmacokinetics in mice
by: Shufang Liu, et al.
Published: (2023-12-01)

Biosimilars - advantages and prospects
by: A. A. Lidzhiyeva, et al.
Published: (2018-02-01)

Development and pharmacokinetic assessment of a fully canine anti-PD-1 monoclonal antibody for comparative translational research in dogs with spontaneous tumors
by: Sho Yoshimoto, et al.
Published: (2023-12-01)

Pharmacokinetic relationships in psychotropic drugs effects
by: G. B. Kolyvanov, et al.
Published: (2021-06-01)

Pharmacodynamics, pharmacokinetics, interactions with other drugs, toxicity and clinical effectiveness of proton pump inhibitors
by: Łukasz Wołowiec, et al.
Published: (2025-07-01)

COMPARISON OF PHARMACOKINETICS AND PHARMACODYNAMICS OF THE ORIGINAL AND GENERIC ENALAPRIL IN THE ELDERLY PATIENTS WITH ARTERIAL HYPERTENSION
by: O. P. Bobrova, et al.
Published: (2015-12-01)

Population Pharmacokinetics and Pharmacodynamics with Enterohepatic Recirculation of Co-Medication of Rosuvastatin and Ezetimibe
by: An H, et al.
Published: (2025-06-01)

REGULATORY STRATEGY OF CLINICAL DEVELOPMENT FOR FIXED COMBINATION MEDICINAL PRODUCTS
by: K. A. Yatsenko, et al.
Published: (2019-01-01)

Validation of Enzyme Immunoassay for Preclinical Pharmacokinetic Trials of Rituximab
by: V. V Pisarev, et al.
Published: (2019-06-01)

Analysis of Biopharmaceutical Manufacturing Localisation in Russia Considering the Country of Origin of Active Pharmaceutical Ingredients
by: A. A. Khalimova, et al.
Published: (2024-02-01)

Comparative study of the clinical efficacy of the first domestic bioanalogue of tocilizumab based on the results of a randomized clinical trial of phase III
by: E. V. Akatova, et al.
Published: (2024-12-01)

Are plasma drug concentrations still necessary? Rethinking the pharmacokinetic link in dose–response relationships
by: Nicolas Simon, et al.
Published: (2025-07-01)

A Semi-Mechanistic Mathematical Model of Immune Tolerance Induction to Support Preclinical Studies of Human Monoclonal Antibodies in Rats
by: Paridhi Gupta, et al.
Published: (2025-06-01)

CLINICAL AND PHARMACOLOGICAL APPROACHES TO OPTIMIZE THE DOSING REGIMEN OF ANTIBACTERIAL DRUGS IN PEDIATRICS
by: Natal’ya B. Lazareva, et al.
Published: (2018-04-01)

A Comparative Parallel Study of Pharmacokinetics and Immunogenicity Following Single Intravenous Administration of Bevacizumab Biosimilar RPH-001 (Manufactured by R-Pharm Group, Russia) and Avastin® (Manufactured by F. Hoffmann-La Roche Ltd., Switzerland) in Healthy Male Volunteers
by: M. A. Kolganova, et al.
Published: (2019-09-01)

EXPERT EVALUATION OF PRECLINICAL STUDIES OF PRIMARY AND SECONDARY PHARMACODYNAMICS OF MEDICINES
by: G. N. Engalycheva, et al.
Published: (2018-12-01)

Are bactericidal antibiotics necessary to effectively treat bloodstream infections?
by: Amy Pulikeyil, et al.
Published: (2025-06-01)

The Changing Landscape of Antibiotic Treatment: Reevaluating Treatment Length in the Age of New Agents
by: Francesca Serapide, et al.
Published: (2025-07-01)